High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes - Wikidata - wikimedia - TriplyDB

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

http://www.wikidata.org/entity/Q34208626

about

Immunotherapy of systemic sclerosis SLE - hematopoietic stem cell transplantation for systemic lupus erythematosus Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?Targeting of natural killer cells by rabbit antithymocyte globulin and campath-1H: similar effects independent of specificity Hematopoietic cell transplantation for Crohn's disease; is it time?Efforts to prevent and halt autoimmune beta cell destruction.Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases).Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.Stem cells in clinical practice: applications and warnings.High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry.A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease Cell therapy for autoimmune diseases High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions.Treatment of systemic sclerosis: potential role for stem cell transplantation.Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation.Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research.Evidence-based management of rapidly progressing systemic sclerosis.Manufacture of Autologous CD34+ Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

P2860

Q24634395-60B980BA-72C4-49AF-8B3D-6C6FC8494726 Q24797491-F769DA3F-004A-4C4D-A49E-F91CDD9C5611 Q33314922-2A219BF4-2314-461A-BD72-8CF2E583AB92 Q33415472-05AF8187-E3E5-43FE-A212-9791F28AC30A Q34017756-FC6BCC71-567A-45FE-81D5-63CBE2AED9F9 Q34077363-018A2177-D8A6-48A0-8CBC-49B288C034A6 Q34207677-77260B2C-285A-459D-9741-536FDCB644BC Q34208618-FF0B13B0-EB94-4D2A-9073-B24874AAADAF Q34208641-284B42B2-F941-4FC8-A5F8-0889D499F339 Q34237823-E0C322AD-F770-4604-BAA7-C5D57E24E3B2 Q34372648-FB62FFFF-8B0E-4E3B-A8F2-E215B137AAB0 Q34552765-9C16FB41-3CF9-4B49-92A2-115DFB8AF26B Q34986999-37F755B8-4686-4D28-88AF-C092A646BC28 Q35554404-51618832-3D61-49E4-A921-6A46844F8A28 Q35636989-8558F099-270F-4302-8B06-727007F4503F Q35868954-13FCDE02-2DFA-486F-882D-38AC5FC364F5 Q35925071-A5C597E2-DA30-4A9B-BED3-095BF8924D5B Q36020897-666B06CE-2095-444E-ADCD-D0150F766A02 Q36164087-54BAC481-8632-48BE-9EA4-3ED64EF2DC2D Q37194001-01591D0C-6FFF-4C79-928C-EDFC97EFAD5B Q37246074-F9ED3E34-593F-44C5-B24B-F90168C7F92C Q37632215-62A595BC-F0D8-40C3-AB95-3CD4D5F813AD Q37763779-3125612D-9B0C-4E27-8CFB-465280075256 Q40177200-70B99FDC-F2F1-45D9-A3C0-F92402F6978F Q42122199-6BB0856D-A1B9-45D9-B6CE-5641240C083B Q42698900-FD20D5E4-354B-4B25-B1DF-B5E061FA029D Q47180993-B08CA441-40F8-45AB-AAC2-E3AB67BF8F33

P2860

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

http://www.wikidata.org/entity/Q34208626

description

2002 nî lūn-bûn

@nan

2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@ast

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@en

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@nl

type

label

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@ast

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@en

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@nl

prefLabel

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@ast

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@en

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@nl

P1433

Q34208626-641D02C4-E3AC-49C8-8425-679935EEBFBA

P1476

Q34208626-6C47EBE9-2973-4CD2-BDD6-7AEE14270D40

P2093

Q34208626-11690F2B-4E73-4B9E-827A-3BF925D8C05F

Q34208626-19F35DC8-64D8-4026-A4D0-2E2C0B895411

Q34208626-23F8ABDF-DF68-47CA-959A-12F7264A7ADF

Q34208626-3826B293-77BD-466E-AD3E-94FB5B921928

Q34208626-3D394791-5DFD-47A0-9EE0-2726E56E72C0

Q34208626-43B9363F-C405-4792-BB15-15B5788B0AAE

Q34208626-5E806041-54CB-49F1-B431-EBD9393DA38F

Q34208626-5FF2EC07-E41C-40A8-8270-4A8620F79EB1

Q34208626-936D4DCB-CA2D-48DA-9823-7837F9D33217

Q34208626-A01F921C-E22F-4097-8171-7AE56757BE4B

P2860

Q34208626-09686976-FC64-4618-99EE-9A31E53562A7

Q34208626-12D78D7D-75EC-4173-B9C8-0A2715CBF571

Q34208626-19F58940-F7EE-4625-B85A-677CEA0F83C2

Q34208626-1CDE3510-6E5E-4BD4-884F-610F3B21D962

Q34208626-2DAE9EFF-F097-436A-8888-E3CFA4C1C530

Q34208626-2FC5AD64-24FE-44CD-9C79-4E8953ABCB83

Q34208626-3A4C4DEE-CE0C-42F2-BF27-CC1F2074DB02

Q34208626-3D163E93-C58E-4942-B438-B4F16BEECEC2

Q34208626-3DF4F750-7D76-4BA2-A768-254BCB996690

Q34208626-3E6B8335-2461-428E-B1C4-E3A2B49C967B

P304

Q34208626-DBDD49D3-D89D-4C90-B7C6-3278F83FAFB9

P31

Q34208626-F8591EF8-102D-40F5-A290-7D9B2064182E

P407

Q34208626-29FD9B3C-D851-4EED-941D-8EBC49426741

P433

Q34208626-87483581-B265-422C-A6BE-888F2849B313

P478

Q34208626-376865E2-E066-477E-B460-E36A5D683E51

P50

Q34208626-29B53A11-F999-49B8-88C6-9600BC17442F

Q34208626-FA2FFB7A-89A5-4912-8AA7-F469A0FDAD3E

P577

Q34208626-6C5D7F60-4CE2-45B7-B21D-96905F923DB2

P698

Q34208626-48383BB6-33AB-454E-8C3C-FB6B47CC0C55

P932

Q34208626-9EA5AC7D-DA49-45F9-83FA-5513BCAF7D7C

P1433

P1476

High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes

@en

P2093

C S Chen

http://www.w3.org/2001/XMLSchema#string

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

J Lee Nelson

http://www.w3.org/2001/XMLSchema#string

Jan Storek

http://www.w3.org/2001/XMLSchema#string

John Rambharose

http://www.w3.org/2001/XMLSchema#string

Julie Sunderhaus

http://www.w3.org/2001/XMLSchema#string

Katherine Ryan

http://www.w3.org/2001/XMLSchema#string

Ken Russell

http://www.w3.org/2001/XMLSchema#string

Kevin T McDonagh

http://www.w3.org/2001/XMLSchema#string

Leona A Holmberg

http://www.w3.org/2001/XMLSchema#string

P2860

Collection of hematopoietic stem cells from patients with autoimmune diseases.

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide.

Autologous haematopoietic stem cell transplants for autoimmune disease--feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Aga

The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo.

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

Predictive value of pulmonary function tests before marrow transplantation.

Epstein-Barr virus lymphoproliferation after bone marrow transplantation.

The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time.

Early and late interstitial pneumonia following human bone marrow transplantation.

Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee

P304

1602-1610

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Rainer F. Storb

Keith M. Sullivan

P577

2002-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12176878

http://www.w3.org/2001/XMLSchema#string

P932

2956742

http://www.w3.org/2001/XMLSchema#string